Linhui Pan

Enhancing the Efficacy and Safety of Doxorubicin against Hepatocellular Carcinoma through a Modular Assembly Approach: The Combination of Polymeric Prodrug Design, Nanoparticle Encapsulation, and Cancer Cell-Specific Drug Targeting.

Haiyang Xie, Lin Zhou, Shusen Zheng, 2018, ACS applied materials & interfaces.

Prediction of tumor recurrence by distinct immunoprofiles in liver transplant patients based on mass cytometry.

Haiyang Xie, Shusen Zheng, Xu‐yong Wei, 2022, American journal of cancer research.

Multi-omics profiling reveals Chitinase-3-like protein 1 as a key mediator in the crosstalk between sarcopenia and liver cancer

Shusen Zheng, Hao Chen, Xu‐yong Wei, 2022, Redox biology.

The positive and negative rumination scale: Development and preliminary validation

Hongfei Yang, Linhui Pan, Jiaxiu Song, 2018, Current Psychology.

The association between donor genetic variations in one-carbon metabolism pathway genes and hepatitis B recurrence after liver transplantation.

Haiyang Xie, Shusen Zheng, D. Lu, 2018, Gene.

Metabolomic biomarkers for the diagnosis and post-transplant outcomes of AFP negative hepatocellular carcinoma

Shusen Zheng, Hao Chen, Xu‐yong Wei, 2023, Frontiers in Oncology.

USP14 promotes K63‐linked RIG‐I deubiquitination and suppresses antiviral immune responses

Linhui Pan, Jianzhong Shen, Juan Yu, 2018, European journal of immunology.

Model for end-stage liver disease-dependent prognostic capacity of platelet-to-lymphocyte ratio following liver transplantation for hepatocellular carcinoma.

D. Lu, Chiyu He, Jianyong Zhuo, 2024, Transplant immunology.